ImmuPharma plc (AIM:IMM)

ImmuPharma Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	0.7	1.35	0.24	0.21	0.67	1.65
Cash & Short-Term Investments	0.7	1.35	0.24	0.21	0.67	1.65
Cash Growth	75.43%	470.81%	13.63%	-68.78%	-59.51%	-71.86%
Accounts Receivable	-	-	-	-	0.17	-
Other Receivables	0.29	0.39	0.43	0.69	1.18	1.13
Receivables	0.29	0.39	0.43	0.69	1.34	1.13
Prepaid Expenses	-	0.07	0.06	0.02	0.07	0.05
Other Current Assets	0.72	-	0.15	0.43	0.25	0.51
Total Current Assets	1.71	1.81	0.88	1.34	2.34	3.35
Property, Plant & Equipment	0.06	0.06	0.08	0.1	0.39	0.35
Long-Term Investments	-	-	-	0.64	0.69	1.42
Other Intangible Assets	-	-	0.01	0.04	0.07	0.07
Long-Term Deferred Charges	-	-	-	0.4	0.4	0.4
Other Long-Term Assets	1.32	-	-	0.18	0.08	0.41
Total Assets	3.1	1.88	0.98	2.72	3.97	6

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1.28	0.19	0.51	0.78	1.07	1.16
Accrued Expenses	-	0.88	0.89	0.77	0.2	0.16
Short-Term Debt	-	-	-	-	0	0
Current Portion of Long-Term Debt	-	-	-	-	-	0
Current Income Taxes Payable	-	0.13	0.12	0.12	0.18	0.27
Total Current Liabilities	1.28	1.19	1.52	1.67	1.45	1.58
Total Liabilities	1.28	1.19	1.52	1.67	1.45	1.58

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	31.9	30.68	29.81	29.81	28.98	28.5
Additional Paid-In Capital	36.22	31.36	29.32	29.32	28.79	27.24
Retained Earnings	-72.42	-67.72	-65.91	-64.08	-61.12	-56.58
Comprehensive Income & Other	6.13	6.37	6.24	6.01	5.87	5.26
Shareholders' Equity	1.82	0.69	-0.54	1.06	2.52	4.41
Total Liabilities & Equity	3.1	1.88	0.98	2.72	3.97	6

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	-	-	-	-	0	0
Net Cash (Debt)	0.7	1.35	0.24	0.21	0.67	1.65
Net Cash Growth	75.43%	470.81%	13.63%	-68.78%	-59.50%	-68.42%
Net Cash Per Share	0.00	0.00	0.00	0.00	0.00	0.01
Filing Date Shares Outstanding	625.29	502.72	416.44	416.44	333.4	284.98
Total Common Shares Outstanding	625.29	502.72	416.44	416.44	333.4	284.98
Working Capital	0.44	0.62	-0.64	-0.32	0.89	1.76
Book Value Per Share	0.00	0.00	-0.00	0.00	0.01	0.02
Tangible Book Value	1.82	0.69	-0.55	1.01	2.45	4.34
Tangible Book Value Per Share	0.00	0.00	-0.00	0.00	0.01	0.02
Machinery	-	0.15	0.14	0.19	1.26	1.1

Data Source: S&P Global Market Intelligence Last updated: Sep 15, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 25, 2026

Data Sources Report a data error